Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 1;22(3):e377-e382.
doi: 10.4317/medoral.21706.

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

S Dikicier  1 , E Dikicier, U Karacayli, B Erguder
Affiliations

Radiodensitometric study for evaluation of bone mineral density around dental implants after zoledronic acid treatment in ovariectomized rats

S Dikicier et al. Med Oral Patol Oral Cir Bucal. .

Abstract

Background: The purpose of this study was to evaluate the effects of intravenous zoledronic acid applied systemically on osseointegration of dental implants and the surrounding bone mineral density (BMD) in the ovariectomized rats.

Material and methods: 36 rats were divided into three groups: control (CTRL), ovariectomy (OVX), and ovariectomy-zoledronic acid (OVX/ZOL). The rats in the CTRL group underwent sham surgery, while rats in OVX and OVX / ZOL group underwent ovariectomy. After 12 weeks, rats from OVX / ZOL were injected with 0.04 mg/kg ZOL intravenously once a week for 6 weeks. The rats from CTRL and OVX groups were injected with 0.9% NaCl. Implants were placed in the left tibia. After 8 weeks, rats were sacrificed and tibia bones were removed for radiodensitometric examination. Digital radiographs of bones' lateral surface were taken. The BMD was measured by using radiographic analysis software.

Results: Statistically significant differences were found between all groups (p<0.05). While highest mean BMD values were observed in the CTRL group, the lowest were in the OVX group.

Conclusions: The systemic use of ZOL has increased the bone density around the implants inserted osteoporotic rat tibia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement:The authors have declared that no conflict of interest exist.

Figures

Figure 1
Figure 1
Custom made titanium micro-implant and screw.
Figure 2
Figure 2
Radiological view and radiodensitometric analysis of the micro-implant.
Figure 3
Figure 3
Differences in BMD parameters between CTRL, OVX/ZOL, and OVX groups. Bone mineral density (BMD), control group (CTRL), ovariectomy group(OVX), and ovariec- tomy-zoledronic acid group (OVX/ZOL).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gómez-de Diego R, Mang-de la Rosa Mdel R, Romero-Pérez MJ, Cutando-Soriano A, López-Valverde-Centeno A. Indications and contraindications of dental implants in medically compromised patients: Update. Med Oral Patol Oral Cir Bucal. 2014;19:483–9. - PMC - PubMed
    1. Giro G, Gonçalves D, Sakakura CE, Pereira RM, Marcantonio Júnior E, Orrico SR. Influence of estrogen deficiency and its treatment with alendronate and estrogen on bone density around osseointegrated implants: radiographic study in female rats. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:162–7. - PubMed
    1. Tresguerres IF, Clemente C, Donado M, Gómez-Pellico L, Blanco L, Alobera MA. Local administration of growth hormone enhances periimplant bone reaction in an osteoporotic rabbit model. Clin Oral Implants Res. 2002;13:631–6. - PubMed
    1. Narai S, Nagata S. Effect of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants. 2003;18:218–23. - PubMed
    1. Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S. Bisphosponate-related osteonecrosis of the jaws-characteristics, risk factors, clinical features, and impact on oncological treatment. J Craniomaxillofacial Surg. 2012;40:303–9. - PubMed